Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Super-ARMS: A new method for plasma ESR1 mutation detection.

Clinica chimica acta; international journal of clinical chemistry - 1 Sept 2021

Chen Yinxi, Zhao Xixi, Wang Li, Wu Fei, Zhang Xin, Wu Huizi, Feng Cong, Liu Mengjie, Zhang Yinbin, Zhang Shuqun

Abstract excerpt

BACKGROUND: ESR1 mutation is an important mechanism of drug resistance and recurrence in hormone receptor-positive breast cancer patients during AI treatment. Patient could still benefit from treatment with fulvestrant after ESR1 mutated. OBJECTIVE: At present, there is still no suitable method to detect ESR1 mutation in plasma as clinical promotion method. We aim to improve from ARMS-PCR to get a method with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Polymerase Chain Reaction

Source

Identifiers

PMID: 34048732
DOI: 10.1016/j.cca.2021.05.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Super-ARMS: A new method for plasma ESR1 mutation detection.PMID 34048732Read ↗

ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.Semantic proximity Read ↗

Sensitive quantitation of ESR1 mutations in cell-free DNA from breast cancer patients using base-specific invasive reaction assisted qPCR.Semantic proximity Read ↗

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.Semantic proximity Read ↗

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.Semantic proximity Read ↗

Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.Semantic proximity Read ↗

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Semantic proximity Read ↗

Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot StudySemantic proximity Read ↗

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Semantic proximity Read ↗

Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.Semantic proximity Read ↗

Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.Semantic proximity Read ↗

Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQSemantic proximity Read ↗

ESR1 mutations in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.